MX2014002363A - Formulaciones de antigenos de staphylococcus aureus con adyuvante. - Google Patents

Formulaciones de antigenos de staphylococcus aureus con adyuvante.

Info

Publication number
MX2014002363A
MX2014002363A MX2014002363A MX2014002363A MX2014002363A MX 2014002363 A MX2014002363 A MX 2014002363A MX 2014002363 A MX2014002363 A MX 2014002363A MX 2014002363 A MX2014002363 A MX 2014002363A MX 2014002363 A MX2014002363 A MX 2014002363A
Authority
MX
Mexico
Prior art keywords
staphylococcus aureus
aureus antigens
adjuvanted formulations
metal salt
aureus
Prior art date
Application number
MX2014002363A
Other languages
English (en)
Inventor
Fabio Bagnoli
Barbara Baudner
Simone Bufali
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2014002363A publication Critical patent/MX2014002363A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se puede mejorar la eficiencia de las vacunas de S. aureus al mezclar con adyuvante antígenos de S. aureus con una mezcla de un agonista de TLR (de manera preferente un agonista de TLR7) y una sal metálica insoluble (de manera preferente una sal de aluminio). El agonista de TLR se adsorbe típicamente a la sal metálica. También se puede absorber un antígeno de S. aureus a la sal metálica.
MX2014002363A 2011-09-01 2012-08-31 Formulaciones de antigenos de staphylococcus aureus con adyuvante. MX2014002363A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161530162P 2011-09-01 2011-09-01
US201261607999P 2012-03-07 2012-03-07
PCT/EP2012/067032 WO2013030378A1 (en) 2011-09-01 2012-08-31 Adjuvanted formulations of staphylococcus aureus antigens

Publications (1)

Publication Number Publication Date
MX2014002363A true MX2014002363A (es) 2014-04-14

Family

ID=46763095

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014002363A MX2014002363A (es) 2011-09-01 2012-08-31 Formulaciones de antigenos de staphylococcus aureus con adyuvante.

Country Status (14)

Country Link
US (1) US20140363461A1 (es)
EP (1) EP2763695A1 (es)
JP (1) JP2014525429A (es)
KR (1) KR20140066212A (es)
CN (1) CN104093418A (es)
AU (1) AU2012300765A1 (es)
BR (1) BR112014004782A2 (es)
CA (1) CA2847204A1 (es)
IL (1) IL231104A0 (es)
IN (1) IN2014CN02152A (es)
MX (1) MX2014002363A (es)
RU (1) RU2014112343A (es)
SG (1) SG11201400210RA (es)
WO (1) WO2013030378A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010115175A1 (en) * 2009-04-03 2010-10-07 Momenta Pharmaceticals, Inc. Control of copolymer compositions
ES2443952T3 (es) 2009-09-02 2014-02-21 Novartis Ag Composiciones inmunógenas que incluyen moduladores de la actividad de TLR
JP2013538217A (ja) 2010-09-01 2013-10-10 ノバルティス アーゲー 不溶性金属塩への免疫増強物質の吸着
EP2672989A4 (en) * 2011-02-08 2015-03-11 Integrated Biotherapeutics Inc IMMUNOGENIC COMPOSITION WITH ALPHA-HEMOLYSIN OLIGOPEPTIDES
JP6191082B2 (ja) 2011-03-02 2017-09-06 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム より低用量の抗原および／またはアジュバントを有する混合ワクチン
CA2847204A1 (en) * 2011-09-01 2013-03-07 Novartis Ag Adjuvanted formulations of staphylococcus aureus antigens
CA2865759C (en) * 2012-03-07 2020-07-21 Novartis Ag Immunologically useful arginine salts
CN104159602B (zh) 2012-03-08 2017-10-24 葛兰素史密丝克莱恩生物有限公司 加强疫苗的含佐剂制剂
WO2014033193A1 (en) * 2012-08-31 2014-03-06 Novartis Ag Stabilised proteins for immunising against staphylococcus aureus
US20150202277A1 (en) * 2012-08-31 2015-07-23 Novartis Ag Stabilised proteins for immunising against staphylococcus aureus
TR201910573T4 (tr) * 2012-08-31 2019-08-21 Glaxosmithkline Biologicals Sa Staphylococcus aureus'a karşı bağışıklık kazandırmak için stabilize edilmiş proteinler.
WO2015140108A1 (en) * 2014-03-17 2015-09-24 Gaxosmithkline Biologicals Sa Immunising against staphylococcal bone and joint infections
SI3122378T1 (sl) * 2014-03-26 2020-03-31 Glaxosmithkline Biologicals S.A. Mutantni stafilokokni antigeni
BE1022875B1 (fr) * 2014-03-26 2016-09-30 Glaxosmithkline Biologicals S.A. Compositions pour une immunisation contre staphylococcus aureus
CN105646681B (zh) * 2016-01-21 2021-07-16 浙江海隆生物科技有限公司 一种奶牛金黄色葡萄球菌α-溶血素亚单位疫苗的制备方法及应用
KR20230149857A (ko) 2016-07-07 2023-10-27 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체-애쥬번트 접합체
AR111760A1 (es) 2017-05-19 2019-08-14 Novartis Ag Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
EP3937984A1 (en) 2019-03-15 2022-01-19 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE67769T1 (de) 1983-01-25 1991-10-15 Ciba Geigy Ag Neue peptidderivate.
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
WO1994021292A1 (en) 1993-03-23 1994-09-29 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
NZ570750A (en) 2003-07-24 2009-12-24 Merck & Co Inc Polypeptides for inducing a protective immune response against staphylococcus aureus
US20060188515A1 (en) 2003-07-24 2006-08-24 Anderson Annaliesa S Polypeptides for inducing a protective immune response against staphylococcus aureus
US20070134263A1 (en) 2004-02-18 2007-06-14 Anderson Annaliesa S Polypeptides for inducing a protective immune response against staphyloococcus aureus
TWI382019B (zh) 2005-08-19 2013-01-11 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯
TW200801003A (en) 2005-09-16 2008-01-01 Astrazeneca Ab Novel compounds
US20090099216A1 (en) 2005-09-22 2009-04-16 Astrazeneca Aktiebolag A Corporation Of Sweden Novel adenine compound
EP1939198A4 (en) 2005-09-22 2012-02-15 Dainippon Sumitomo Pharma Co NEW ADENINE CONNECTION
US20090118263A1 (en) 2005-09-22 2009-05-07 Dainippon Sumitomo Pharma Co., Ltd. Novel Adenine Compound
JPWO2007034917A1 (ja) 2005-09-22 2009-03-26 大日本住友製薬株式会社 新規なアデニン化合物
TW200745114A (en) 2005-09-22 2007-12-16 Astrazeneca Ab Novel compounds
WO2007093901A1 (en) 2006-02-17 2007-08-23 Pfizer Limited 3 -deazapurine derivatives as tlr7 modulators
CA2655133C (en) 2006-06-12 2018-03-20 Nabi Biopharmaceuticals Use of alpha-toxin for treating and preventing staphylococcus infections
JP2009542645A (ja) 2006-07-05 2009-12-03 アストラゼネカ・アクチエボラーグ Ｔｌｒ７のモジュレーターとして作用する８−オキソアデニン誘導体
WO2008005555A1 (en) 2006-07-07 2008-01-10 Gilead Sciences, Inc. Modulators of toll-like receptor 7
WO2008152447A2 (en) 2006-10-30 2008-12-18 The University Of Western Ontario Staphylococcus aureus specific anti-infectives
US20100120799A1 (en) 2007-02-19 2010-05-13 Smithkline Beecham Corporation Purine derivatives as immunomodulators
PE20081887A1 (es) 2007-03-20 2009-01-16 Dainippon Sumitomo Pharma Co Nuevo compuesto de adenina
JP5400763B2 (ja) 2007-05-08 2014-01-29 アストラゼネカ・アクチエボラーグ 免疫調節特性を有するイミダゾキノリン類
EP2188280B1 (en) 2007-08-03 2011-03-09 Pfizer Limited Imidazopyridinones
JP5658564B2 (ja) 2007-08-31 2015-01-28 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ ブドウ球菌肺疾患および状態に対する免疫に関連した方法および組成物
PE20091236A1 (es) 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
NZ588191A (en) 2008-03-03 2012-06-29 Irm Llc Compounds and compositions as tlr activity modulators
NZ599446A (en) 2008-03-24 2013-11-29 4Sc Discovery Gmbh Novel substituted imidazoquinolines
DK2313111T3 (da) 2008-08-01 2013-12-02 Ventirx Pharmaceuticals Inc Toll-lignende receptoragonistformuleringer og anvendelse deraf
CN102272134B (zh) 2008-12-09 2013-10-16 吉里德科学公司 Toll样受体调节剂
NZ612315A (en) * 2009-04-14 2014-10-31 Novartis Ag Compositions for immunising against staphylococcus aureus
CA2766629C (en) * 2009-06-22 2020-03-24 Wyeth Llc Immunogenic compositions of staphylococcus aureus antigens
WO2011007004A1 (en) 2009-07-16 2011-01-20 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Treatment of infections
GB0913681D0 (en) * 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
TWI445708B (zh) * 2009-09-02 2014-07-21 Irm Llc 作為ｔｌｒ活性調節劑之化合物及組合物
ES2443952T3 (es) * 2009-09-02 2014-02-21 Novartis Ag Composiciones inmunógenas que incluyen moduladores de la actividad de TLR
EA023725B1 (ru) 2010-03-23 2016-07-29 Новартис Аг Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
JP2013538217A (ja) 2010-09-01 2013-10-10 ノバルティス アーゲー 不溶性金属塩への免疫増強物質の吸着
JP6191082B2 (ja) * 2011-03-02 2017-09-06 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム より低用量の抗原および／またはアジュバントを有する混合ワクチン
CA2847204A1 (en) * 2011-09-01 2013-03-07 Novartis Ag Adjuvanted formulations of staphylococcus aureus antigens
JP2015510872A (ja) * 2012-03-07 2015-04-13 ノバルティス アーゲー Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ抗原の増強された製剤
CN104159603A (zh) * 2012-03-08 2014-11-19 诺华股份有限公司 带有tlr4激动剂的联合疫苗
CN104159602B (zh) * 2012-03-08 2017-10-24 葛兰素史密丝克莱恩生物有限公司 加强疫苗的含佐剂制剂
JP2015528456A (ja) * 2012-08-31 2015-09-28 ノバルティス アーゲー Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓに対する免疫化のための安定化されたタンパク質
TR201910573T4 (tr) * 2012-08-31 2019-08-21 Glaxosmithkline Biologicals Sa Staphylococcus aureus'a karşı bağışıklık kazandırmak için stabilize edilmiş proteinler.
WO2014033193A1 (en) * 2012-08-31 2014-03-06 Novartis Ag Stabilised proteins for immunising against staphylococcus aureus
US20150202277A1 (en) * 2012-08-31 2015-07-23 Novartis Ag Stabilised proteins for immunising against staphylococcus aureus
US9526776B2 (en) * 2012-09-06 2016-12-27 Glaxosmithkline Biologicals Sa Combination vaccines with serogroup B meningococcus and D/T/P
GB201219420D0 (en) * 2012-10-29 2012-12-12 Novartis Ag Staphyloccal immunogens
BR112015018014A2 (pt) * 2013-02-01 2017-07-11 Glaxosmithkline Biologicals Sa liberação intradérmica de composições imunológicas compreendendo agonistas do receptor do tipo toll
WO2015140108A1 (en) * 2014-03-17 2015-09-24 Gaxosmithkline Biologicals Sa Immunising against staphylococcal bone and joint infections
SI3122378T1 (sl) * 2014-03-26 2020-03-31 Glaxosmithkline Biologicals S.A. Mutantni stafilokokni antigeni
BE1022875B1 (fr) * 2014-03-26 2016-09-30 Glaxosmithkline Biologicals S.A. Compositions pour une immunisation contre staphylococcus aureus

Also Published As

Publication number Publication date
SG11201400210RA (en) 2014-03-28
CN104093418A (zh) 2014-10-08
EP2763695A1 (en) 2014-08-13
IN2014CN02152A (es) 2015-09-04
WO2013030378A1 (en) 2013-03-07
JP2014525429A (ja) 2014-09-29
AU2012300765A1 (en) 2014-03-13
BR112014004782A2 (pt) 2017-03-21
CA2847204A1 (en) 2013-03-07
KR20140066212A (ko) 2014-05-30
IL231104A0 (en) 2014-04-30
US20140363461A1 (en) 2014-12-11
RU2014112343A (ru) 2015-10-10

Similar Documents

Publication Publication Date Title
MX2014002363A (es) Formulaciones de antigenos de staphylococcus aureus con adyuvante.
ZA201500316B (en) Novel compound with effects of thrombolysis, free radical scavenging and thrombus-targeting as well as preparation method and use thereof
EP3071229A4 (en) Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
EP2680885B8 (en) Combination vaccines with lower doses of antigen and/or adjuvant
HK1202050A1 (en) Lyophilised and aqueous anti-cd40 antibody formulations cd40
IN2014CN04251A (es)
EP2997246A4 (en) Piston having combustion bowl shaped to balance combustion efficiency and emission properties
MX2015014500A (es) Terapia de combinacion de anticuerpos contra csf-1r y agonista de tlr9.
BR112014031310A2 (pt) anticorpos anti-pcsk9, formulações, dosagem e métodos de uso
EP2992089A4 (en) Use of anti-cd47 agents to enhance immunization
HK1227279A1 (zh) 在斷奶之前對抗豬繁殖與呼吸綜合徵(prrs)病毒的有效疫苗接種
MX2014010417A (es) Formulaciones adyuvadas de vacunas de difteria, tetanos y tos ferina (dtp) de refuerzo.
EP3089754A4 (en) Single vial vaccine formulations
NZ705606A (en) Methods for identifying antibodies with reduced immunogenicity
HK1197370A1 (en) Stable immunogenic compositions of staphylococcus aureus antigens
MX2015002482A (es) Composicion inmunogenica.
BR112015023523B8 (pt) Composições farmacêuticas e recipiente de forma de dosagem única
EP2726097A4 (en) HERPES VIRUS VACCINE AND METHOD OF USE
WO2014127378A8 (en) Design of short oligonucleotides as vaccine adjuvants and therapeutic agents
EP3010340A4 (en) Compositions and methods for potentiating immune response, enhancing immunotherapy, and increasing vaccine potency
IN2014CN03454A (es)
MY166052A (en) Freeze-Dried Aripiprazole Formulation
WO2013033496A3 (en) Laser adjuvants for enhancing immune response
PT2575872T (pt) Concentração de antigénios da vacina da gripe sem liofilização
EP2968500A4 (en) VACCINES WITH ONE ANTIGEN AND INTERLEUKIN-23 AS ADJUVANS